Madsen Lise, Petersen Rasmus K, Sørensen Morten B, Jørgensen Claus, Hallenborg Philip, Pridal Lone, Fleckner Jan, Amri Ez-Zoubir, Krieg Peter, Furstenberger Gerhard, Berge Rolf K, Kristiansen Karsten
Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense M, Denmark.
Biochem J. 2003 Nov 1;375(Pt 3):539-49. doi: 10.1042/bj20030503.
Adipocytes play a central role in whole-body energy homoeostasis. Complex regulatory transcriptional networks control adipogensis, with ligand-dependent activation of PPARgamma (peroxisome proliferator-activated receptor gamma) being a decisive factor. Yet the identity of endogenous ligands promoting adipocyte differentiation has not been established. Here we present a critical evaluation of the role of LOXs (lipoxygenases) during adipocyte differentiation of 3T3-L1 cells. We show that adipocyte differentiation of 3T3-L1 preadipocytes is inhibited by the general LOX inhibitor NDGA (nordihydroguaiaretic acid) and the 12/15-LOX selective inhibitor baicalein. Baicalein-mediated inhibition of adipocyte differentiation was rescued by administration of rosiglitazone. Treatment with baicalein during the first 4 days of the differentiation process prevented adipocyte differentiation; supplementation with rosiglitazone during the same period was sufficient to rescue adipogenesis. Accordingly, we demonstrate that adipogenic conversion of 3T3-L1 cells requires PPARgamma ligands only during the first 4 days of the differentiation process. We show that the baicalein-sensitive synthesis of endogenous PPARgamma ligand(s) increases rapidly upon induction of differentiation and reaches a maximum on days 3-4 of the adipocyte differentiation programme. The conventional platelet- and leucocyte-type 12(S)-LOXs and the novel eLOX-3 (epidermis-type LOX-3) are expressed in white and brown adipose tissue, whereas only eLOX-3 is clearly expressed in 3T3-L1 cells. We suggest that endogenous PPARgamma ligand(s) promoting adipocyte differentiation are generated via a baicalein-sensitive pathway involving the novel eLOX-3.
脂肪细胞在全身能量稳态中发挥着核心作用。复杂的调控转录网络控制着脂肪生成,其中过氧化物酶体增殖物激活受体γ(PPARγ)的配体依赖性激活是一个决定性因素。然而,促进脂肪细胞分化的内源性配体的身份尚未确定。在这里,我们对脂氧合酶(LOXs)在3T3-L1细胞脂肪细胞分化过程中的作用进行了批判性评估。我们发现,3T3-L1前脂肪细胞的脂肪细胞分化受到通用LOX抑制剂去甲二氢愈创木酸(NDGA)和12/15-LOX选择性抑制剂黄芩苷的抑制。罗格列酮的给药可挽救黄芩苷介导的脂肪细胞分化抑制作用。在分化过程的前4天用黄芩苷处理可阻止脂肪细胞分化;在同一时期补充罗格列酮足以挽救脂肪生成。因此,我们证明3T3-L1细胞的脂肪生成转化仅在分化过程的前4天需要PPARγ配体。我们发现,内源性PPARγ配体的黄芩苷敏感合成在分化诱导后迅速增加,并在脂肪细胞分化程序的第3-4天达到最大值。传统的血小板型和白细胞型12(S)-LOXs以及新型表皮型LOX-3(eLOX-3)在白色和棕色脂肪组织中表达,而只有eLOX-3在3T3-L1细胞中明显表达。我们认为,促进脂肪细胞分化的内源性PPARγ配体是通过一条涉及新型eLOX-3的黄芩苷敏感途径产生的。